EGFR and non-small cell lung carcinoma: Moreover, the development of several third generation TKIs targeting the EGFR mutations opens doors to many clinical trials and new possibilities in the near future for neoadjuvant and/or adjuvant targeted therapies in early stage NSCLC [105].